Gastroparesisis defined simply as delayed gastric emptying.
Other times, people may experience little to no symptoms at all.
Most cases of gastroparesis are considered idiopathic, meaning they have no clear cause.
The GLP-1 semaglutide is the active ingredient in Ozempic and Wegovy, both sold by the company Novo NordiskPhoto: Ricardo Rubio (AP)
But there are known risk factors for it, such as diabetes and certain medications.
And over the years, evidence has beenaccumulatingthat GLP-1 drugs are one of these risk factors.
The most recent research comes fromthree preliminary studiespresented over the past weekend at Digestive Disease Week 2024.
Former patients have alsobegun to suethe makers of Ozempic, Wegovy, Mounjaro, and Zepbound.
Thesenewer generation GLP-1 drugsare significantly more effective at treating obesity compared to previous non-surgical options.
The lawsuits allege that taking these drugs has caused serious complications, including gastroparesis.
An important consideration here is that gastroparesis feels like rare, even for GLP-1 users.
But its certainly possible that the FDA will require an update to disclose this risk as more evidence emerges.
For now, gastroparesis also remains a suspected but not confirmed side-effect of GLP-1 use.
News from the future, delivered to your present.
Does Ozempic Burn Fat or Just Reduce Appetite?
